Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 2, 1999, Pages 68-74

  Forus, A ^a   Hoifodt H K ^a   Overli G E T ^a   Myklebost, O ^a   Fodstad, O ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bone marrow aspirates; Breast cancer; erbB2; Fluorescent in situ hybridisation; int2

Indexed keywords

ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0032894775     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.2.68     Document Type: Article

References (31)

1. Fisher B, Bauer M, Wickerham LL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 1983;52:1551-7.
2. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
3. Cote RJ, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9:1749-56.
4. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastasis in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
5. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Int 1996;88:1652-8.
6. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994;3:315-22.
7. de Graaf H, Maelandsmo GM, Ruud P, et al. Ectopic expression of target genes may represent an inherent limitation of RT-PCR used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. Int J Cancer 1997;72:191-6.
8. Fodstad Ø, Høfødt HK, Rye PD, et al. New immunobead techniques for sensitive detection of malignant cells in blood and bone marrow. Proceedings of the American Association for Cancer Research 1996;37:214.
9. Fodstad Ø, Trones GE, Forus A, et al. Improved immunomagnetic method for detection and characterization of cancer cells in blood and bone marrow. Proceedings of the American Association for Cancer Research 1997;38:26.
10. Naume B, Borgen E, Beiske K, et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 1997;6:103-14.
11. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/NEU oncogene. Science 1987;235:17782.
12. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescent in situ hybridization. Oncogene 1996;13:63-72.
13. Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11-18.
14. Champeme MH, Bieche I, Hacene K, et al. INT2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB2/neu amplification in primary breast cancer. Mod Pathol 1994;7:900-5.
15. Henry JA, Hennessy C, Levett DL, et al. INT-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB2 and c-myc. Int J Cancer 1993;53:774-80.
16. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
17. Slamon D, Godolphin W, Jones LA, et al. Studies of the HER-2/NEU proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
18. Borg Å, Tandon AK, Sigurdsson H, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
19. Parkes HC, Lillycrop K, Howell A, et al. C-erbB2 mRNA expression in human breast tumors: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 1990;61:39-45.
20. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
21. Champeme HM, Bieche I, Lizard S, et al. 11q13 amplification in local recurrence of human primary breast cancer. Genes Chromosomes Cancer 1995;12:128-33.
22. Press MF, Bernstein L, Thomas PA, et al. Her2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinoma. J Clin Oncol 1997;15:2894-904.
23. de Leij L, Postmus PE, Popperna S, et al. The use of monoclonal antibodies for the pathological diagnosis of lung cancer. In: Hansen HH, ed. Lung cancer: basic and clinical aspects. Boston: Martinus Nijhoff Publisher, 1986:31-48.
24. Forus A, Berner J-M, Meza-Zepeda LA, et al. Molecular characterisation of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. Br J Cancer 1998;78:495-503.
25. Rye PD, Høifødt HK, Øverli GET, et al. Immunobead filtration. A novel approach for the isolation and propagation of tumor cells. Am J Pathol 1997;150:99-106.
26. Zojer N, Fiegl M, Mullauer L, et al. Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusion from breast cancer patients. Br J Cancer 1997;75:403-7.
27. Mueller P, Carroll P, Bowers E, et al. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma are cytogenetically aberrant. Cancer 1998;83:538-46.
28. Beiske K, Myklebust AT, Aamdal S, et al. Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol 1992;141:531-8.
29. Myklebust AT, Beiske K, Pharo A, et al. Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis. Br J Cancer Suppl 1991;14:49-53.
30. Naume B, Borgen E, Nesland JM, et al. Increased sensitivity for detection of micrometastases in bone marrow/ peripheral blood stem cell products from breast cancer patients by negative immunomagnetic separation. Int J Cancer 1998;78:556-60.
31. Borgen E, Beiske K, Trachsel S, et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185:427-34.